Retinoic acid-inducible gene I (RIG-I) receptor recognizes 5′-triphosphorylated RNA and triggers a signalling cascade that results in the induction of type-I interferon (IFN)-dependent responses. Its precise regulation represents a pivotal balance between antiviral defences and autoimmunity. To elucidate the cellular cofactors that regulate RIG-I signalling, we performed two global RNA interference analyses to identify both positive and negative regulatory nodes operating on the signalling pathway during virus infection. These factors were integrated with experimentally and computationally derived interactome data to build a RIG-I protein interaction network. Our analysis revealed diverse cellular processes, including the unfolded protein response, Wnt signalling and RNA metabolism, as critical cellular components governing innate responses to non-self RNA species. Importantly, we identified K-Homology Splicing Regulatory Protein (KHSRP) as a negative regulator of this pathway. We find that KHSRP associates with the regulatory domain of RIG-I to maintain the receptor in an inactive state and attenuate its sensing of viral RNA (vRNA). Consistent with increased RIG-I antiviral signalling in the absence of KHSRP, viral replication is reduced when KHSRP expression is knocked down both in vitro and in vivo. Taken together, these data indicate that KHSRP functions as a checkpoint regulator of the innate immune response to pathogen challenge.
A cute innate immune induction is critical for the elimination of viral infection and establishing humoral immunity. Aberrant and unregulated activation of these pathways can result in excessive chemokine production and cytokine storm, chronic inflammation and susceptibility to autoimmunity 1 . The cytoplasmic pattern recognition receptor (PRR) retinoic acidinducible gene I (RIG-I) detects viral infection through recognition of pathogen-associated molecular patterns (PAMPs) encoded by viral RNA (vRNA). RIG-I senses the 5′-triphosphate dsRNA produced during infection by RNA viruses such as influenza A (IAV), Sendai (SeV) and hepatitis C viruses [2] [3] [4] [5] [6] [7] . Binding of vRNA to RIG-I triggers association with mitochondria activating signalling protein (MAVS), which leads to the activation of kinases TBK1/IKK-ε, and the transcription factor IRF3, to induce type-I interferon (IFN) production and expression of additional antiviral responses 8 . Type-I IFN produced in response to RIG-I signalling then activates the secondary circuit, the JAK/STAT pathway, to induce expression of interferon stimulated genes (ISGs) as well as RIG-I to amplify the antiviral innate response (Fig. 1a, left) . It has been extensively reported that RIG-I signalling is a primary innate immune pathway induced by various RNA viruses 2, 5, 8 . A number of regulatory mechanisms have been described that ensure the precise control of RIG-I signalling responses to balance between robust activation to limit viral replication and inhibition of promiscuous activation in the absence of pathogen challenge [9] [10] [11] [12] [13] [14] [15] .
In this study, we describe a comprehensive and systematic interrogation of the cellular factors that govern RIG-I signalling through genome-wide RNA interference (RNAi) and targeted proteomic approaches. Through computational integration of these results, we have constructed a RIG-I pathway protein network, from which we have identified key biological modules and nodes that govern RIG-I signalling, underscoring the involvement of discrete and parallel host cellular processes in controlling innate immune responses to viral infection. Furthermore, from these Figure 1 | Genome-wide RNAi screens to identify regulators of the RIG-I signalling pathway. a, Schematic representation of the RIG-I signalling pathway (left) and genome-wide siRNA screens (right). b, HEK293T ISRE-luciferase cells were transfected with the indicated siRNA followed by infection with either wild-type (WT) or delNS1 IAV. At 24 h.p.i., luciferase activities were analysed. Results are the mean ± s.d. of three biological replicates. ***P < 0.001 (Student's t-test). Data are representative of three independent experiments. c, Primary results of genome-wide screens for positive (left) and negative (right) regulators of RIG-I signalling. ISRE activity score values were calculated as described in the section 'RNAi screening analysis'. Negative controls (red circles) were assigned an activity score of 1, and positive controls (black circles) were scaled to a value of 0.1. Screen hits are shown as open circles. RSA analysis is used to generate P values: *P < 0.05, **P < 0.01, ***P < 0.001. d, Network integration of candidate RIG-I pathway regulators (permutation test P < 0.001). Circles indicate protein interactions identified by GeneGo analysis. Hexagons and squares indicate AP-MS bait and prey interactions, respectively. Confirmed negative regulators (pink), high-confidence positive regulators based on RSA cutoff (orange, P < 0.01) and canonical RIG-I regulators (red and blue) are also shown. An enlarged subnetwork of RIG-I pathway regulators is encircled by a dashed line (right). AP-MS interactions between RNAi hits and canonical RIG-I bait proteins are indicated (red lines). This subnetwork was expanded using GeneGo to the first-neighbour interactors of RNAi hits (indicated by blue lines, right). e, Functional enrichment of RIG-I network proteins using gene ontology resources. Nodes represent enriched functions for an annotated ontology term and node size indicates the number of genes that fall into that term. Pie charts embedded within the nodes represent the percentage of RIG-I positive regulators (green) and negative regulators (red) for that term. Nodes are clustered into subnetworks that encompass a representative description for the annotations.
RIG-I pathway
systems-level studies, we identified the RNA-binding K-Homology splicing regulatory protein (KHSRP) as a potent inhibitor of the RIG-I-dependent immune response. KHSRP associates with the regulatory domain (RD) of RIG-I, reduces vRNA association with RIG-I during viral infection, and represses RIG-I activation. We find that immunostimulatory RIG-I PAMPs displace KHSRP from RIG-I, which coincides with the triggering of RIG-I signalling. Correspondingly, depletion of KHSRP inhibits the replication of RNA viruses both in vitro and in vivo. Taken together, these findings implicate KHSRP as a critical negative regulator of RIG-I-mediated innate sensing, preventing unsanctioned innate induction that may trigger interferonopathies or autoimmune diseases 16, 17 .
Results
Genome-wide RNAi analysis to identify RIG-I pathway regulators. To establish a comprehensive systems-level evaluation of the genes that regulate the cytoplasmic innate immune sensing of RNA viruses, we performed two genome-wide small interfering RNA (siRNA) screens in HEK293T cells containing an interferonstimulated response element (ISRE) fused to a luciferase reporter (see Methods). Infection with either deleted non-structural 1 (NS1) protein (delNS1) IAV or wild-type IAV (PR/8/34) were used to identify positive or negative regulators of RIG-I signalling, respectively ( Fig. 1a ). Because NS1 directly inhibits RIG-I signalling, we used delNS1 IAV to identify positive regulators of RIG-I-mediated innate responses 18, 19 . A complete loss of innate induction upon depletion of RIG-I confirmed that the delNS1 IAV-induced innate response is RIG-I dependent (Fig. 1b, right ). From this positive regulator screen, we identified many previously reported RIG-I signalling members, including MAVS, IRF3 and RIG-I itself ( Fig. 1c , left, and Supplementary Table 1 ), as well as additional factors involved in broader aspects of cellular functions such as viral transcription, messenger RNA (mRNA) processing and metabolism, and epigenetic regulation (see Fig. 1e ).
Conversely, to identify antagonists of RIG-I-dependent innate responses, we assayed for factors that, upon depletion, enhanced ISRE-reporter activity after wild-type IAV infection ( Fig. 1c , right, and Supplementary Table 2 ). As expected, siRNAs targeting NS1 increased ISRE-reporter activity by 4.5-fold relative to non-targeting (nCTL) siRNA control ( Fig. 1b , left, and Supplementary Fig. 1 ) 18 . From this screen, we identified known negative regulators of RIG-I signalling, including CYLD and PIN1 ( Fig. 1c, right) , as well as a number of additional factors that were found to be enriched in discrete orthogonal pathways, for example, the unfolded protein response (UPR), the AMPK signalling pathway, and positive regulation of WNT signalling (see Discussion and Supplementary Discussion) 13, 20 .
Applying redundant siRNA activity (RSA; see Methods), we identified 125 putative positive (P < 0.01) and 115 negative (P < 0.01) regulators (Supplementary Tables 1 and 2) of the RIG-I-dependent innate response pathway 21 . To better understand the biochemical relationships of these putative regulators identified through genetic screens in the context of RIG-I signalling, we performed the global interactome analysis of RIG-I/IRF3 pathway members using affinity-purified mass spectrometry (AP-MS; see Methods and Supplementary Table 4 ). Canonical RIG-I signalling members (RIG-I, MAVS, TRIM25, IKK-ε, TBK1, IRF3), known antagonists (NLRX1, RNF5, A20, CYLD, DHX58, PIN1) and reported regulators (PCBP2, PSMA7, RNF125, STING, EYA4, DDX3X) were FLAG-tagged and subjected to AP-MS. A total of 78 proteins with high statistical confidence were identified from the AP-MS studies. Seventeen overlapped with genes identified by the RNAi screens (P < 0.001) and were integrated into a RIG-I signalling network (see Fig. 1d ) [22] [23] [24] [25] .
Hits from our RNAi screens, a previously published influenza replication screen ( Supplementary Table 3 ) and the described AP-MS data, were used to construct an interaction network of the co-regulators that were mapped to the canonical RIG-I signalling pathway ( Fig. 1d , left, and Supplementary Table 6) 26 . We next extracted subnetworks that were seeded by the factors that were found in both in the RNAi and AP-MS data, and then expanded to the first interacting neighbours using curated protein interaction data sets (GeneGO MetaCore, Fig. 1d , right; see Methods for details). From these networks we identified multiple densely connected network clusters ( Supplementary Fig. 2a-e ). Functional enrichment analyses of 167 nodes in the network using gene ontology resources revealed more than 152 statistically enriched classifications, which could be broadly categorized into 17 related functional groups (Supplementary Table 5 ) encompassing many expected terms such as regulation of viral processes (P = 9.15 × 10 −22 ), negative regulation of type-I IFN production (P = 1.46 × 10 −21 ), cellular response to cytokines (P = 1.38 × 10 −9 ), but also unanticipated functional groups: splicesome (P = 9.95 × 10 −19 ), canonical Wnt signalling (P = 2.87 × 10 −3 ), AMPK signalling (P = 1.04 × 10 −4 ) and the unfolded protein response (P = 1.48 × 10 −6 ) ( Fig. 1e , Discussion and Supplementary Discussion).
Taken together, integration of RNAi and proteomic analyses of the RIG-I pathway has enabled the elucidation of cross-regulatory modules that underscore the role of interdependent, but discrete, biological pathways in shaping the innate immune responses to pathogenic invasion.
Confirmation studies of the putative negative regulators on the RIG-I pathway. To avoid aberrant or prolonged activation of innate signalling that may trigger hypercytokinemia or autoimmune responses, innate immune induction must be tightly controlled, likely through a series of negative regulatory circuits [27] [28] [29] . To better understand the regulation of this process, we focused further studies on the identified antagonists of RIG-I signalling (see Methods and Supplementary Table 3 ).
IRF3-dependent RIG-I signalling results in the induction of type-I IFNs, which in turn stimulates the JAK/STAT pathway in a secondary circuit to further enhance expression of ISGs, including ISG54. To distinguish negative regulators specifically affecting the primary RIG-I activation circuit from those impacting type-I IFN signalling, we generated an IRF9 knockout cell line using CRISPR (cIRF9; Supplementary Fig. 3a) 30 . IRF9 is a critical component of the ISGF3 transcription complex formed upon type-I IFN signalling, and inhibition of IRF9 abolishes ISG54 induction by type-I IFN (ref. 31) . We tested ISG54 mRNA induction upon depletion of 30 of the confirmed factors, which were previously validated in wild-type cells, in these interferon signalling-deficient cells ( Fig. 2a , Supplementary Table 3 and Methods). We found that 28 factors enhanced ISG54 expression by more than 1.5-fold in the absence of type-I IFN signalling, while two genes (ERN2 and S100A13) fell below this cutoff in cIRF9 cells ( Fig. 2a and Supplementary Table 3 , column F). These data suggest that although these two genes are involved in ISG54 expression exclusively through the type-I IFN signalling pathway, the remaining factors at least partially impact innate immune responses through the regulation of RIG-I signalling.
To determine whether the activity of these negative regulators was sufficient to repress RIG-I signalling, we selected 25 genes from the siRNA profiling above and ectopically expressed these factors in ISRE-reporter cells followed by delNS1 IAV infection ( Fig. 2a and Supplementary Table 3 ). Among 25 tested, 13 genes were found to reduce reporter activity by at least 45% (P < 0.05) relative to the value of reverse GFP (RevGFP) negative control ( Fig. 2b and Supplementary Table 3 ). We hypothesize that the remaining genes that did not significantly repress RIG-I signalling may require additional cofactors for their inhibitory activities. Next, to pinpoint specific steps along the signalling pathway at which inhibition occurs by these selected factors, we employed a pathway Table 3 ). Among those factors, expression of 13 genes resulted in a repression of reporter activity by at least 50% compared to activity of the RevGFP negative control. Results are mean ± s.d. of four biological replicates. Data are representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test). c, cDNAs in b were ectopically co-expressed in ISRE-luciferase HEK293T cells with canonical RIG-I signalling members RIG-I 2CARD, MAVS and TBK1. Concentrations of the selected cDNAs were fixed, and canonical RIG-I signalling component cDNAs were titrated over five dilutions. Reporter activities were used to devise a linear regression for each candidate regulator ( Supplementary Fig. 4 ), and the statistical comparison (PRISM) between each antagonist cDNA slope and the slope of the RevGFP control is indicated as a P value and was used to determine whether a cDNA expression blocked (blue) or did not impact (activity, yellow) ISRE-reporter activity induced by transfection of indicated pathway signalling members (P < 0.05, Supplementary Fig. 4 ). Right: schematic for pathway mapping and localization of identified groups. Results are representative of two independent experiments and samples were run in biological quadruplicate. In a-c negative controls are coloured in red and positive controls are coloured in green.
mapping strategy based upon the inhibition profile of each identified negative regulator after induction by specific canonical RIG-I pathway members ( Supplementary Fig. 4a ; see Methods for details). The factors were then grouped into four distinctive categories ( Fig. 2c and Supplementary Table 3 ). For example, ectopic expression of the set denoted as Group B (CAB39, CASP8AP2, PAFAH2, ULK3, PFKFB4, UCKL1) blocked RIG-I-and MAVSdependent, but not TBK1-induced, activation, suggesting that these genes regulate the signalling step between MAVS and TBK1 ( Fig. 2c ). Ectopic A20 expression has been shown to significantly block RIG-I signalling induced by SeV infection and 2CARD RIG-I-induced ISRE activation, but not with TBK1 transactivation, and served as a positive control for this group 32, 33 . Applying analogous reasoning, we mapped the remaining candidate factors into three other categories, as depicted in Fig. 2c (right schematic). We did not find any candidates that exclusively regulated 2CARD RIG-I activation; however, we found four factors (Group C: CAPN10, CLK3, PCK1, PIN1) that act downstream of TBK1 kinase activation, leading to IRF3 phosphorylation (pIRF3). PIN1 was considered as the prototypic member of this functional group because it antagonizes IRF3 activity during RIG-I signalling 13 . We were unable to categorize the activities of two factors (Group D: DTX2, STUB1), because they failed to block the reporter activation by 2CARD RIG-I, but potently inhibited the activation by MAVS, TBK1 and delNS1 IAV infection ( Fig. 2b,c ). This may be due to differences between endogenous RIG-I activity and expression of the 2CARD RIG-I construct used for pathway activation. Finally, we identified one gene (Group A), KHSRP, that failed to block at any point along the pathway ( Fig. 2c , left, and Supplementary  Fig. 4a ), but potently inhibited delNS1 IAV-induced signalling ( Fig. 2b and Supplementary Fig. 4b ), indicating that this protein may impact early steps of RIG-I activation.
KHSRP negatively regulates RIG-I signalling through interaction with the RD domain of RIG-I involved in PAMP sensing. KHSRP depletion by siRNA enhanced ISG54 expression upon delNS1 IAV and SeV infections by fiveto sixfold, similar to knockdown of IRF3 antagonist PIN1 ( Fig. 3a ). Moreover, KHSRP depletion was also sufficient to partially reverse NS1 antagonism during wildtype IAV infection, as demonstrated by 14-fold ISG54 mRNA induction compared to non-targeting control ( Supplementary  Fig. 5a ). Next, we evaluated the role of KHSRP in primary cells that are more relevant to IAV pathogenesis. KHSRP and PIN1 were selectively depleted in cultured undifferentiated normal human bronchial-tracheal epithelial cells (NHBE) and then infected with delNS1 IAV or SeV. KHSRP-depleted primary cells displayed enhanced expression of ISG54 (two-to threefold) compared to non-targeting control cells (P < 0.01) after viral challenge ( Fig. 3b ). Similar to ISG54 mRNA, KHSRP depletion in both 293T and NHBE resulted in enhanced IFNβ mRNA expression post viral infection ( Supplementary Figs 5b and 6b ). KHSRP has previously been reported to regulate the stability of various mRNA species encoded by immune regulatory genes, including type-I IFNs (refs 34,35) . To establish that the enhanced ISG54 expression in the absence of KHSRP does not require the type-I IFN signalling circuit, we used both cIRF9 knockout cells and a type-I IFN neutralization approach, which relies on treatment with an interferon α/β receptor subunit 2 (IFNAR2) decoy to uncouple RIG-I signalling from IFN feedback ( Supplementary  Fig. 3b ). Both the loss of IRF9 and inhibition of IFN signalling utilizing the IFNAR2 decoy treatment did not alter the enhanced ISG54 expression in the absence of KHSRP ( Supplementary  Fig. 3b ), indicating that KHSRP negatively regulates the innate response through direct regulation of RIG-I signalling.
Furthermore, we found that ectopic expression of KHSRP inhibited ISG54 induction ( Fig. 3d , left) and ISRE-reporter activation ( Fig. 2b ) during delNS1 IAV infection by 60 and 75%, respectively. Importantly, ectopic KHSRP expression also inhibited IRF3 phosphorylation (S386) and STAT1 phosphorylation (pSTAT), key steps in RIG-I/IFN signalling, in a dose-dependent manner relative to control (LacZ, Fig. 3d, right) . Conversely, knockout of KHSRP using CRISPR (cKHSRP) enhanced ISG54 expression upon IAV challenge by sevenfold ( Supplementary Fig. 6a ,b, left), or SeV infection by 40-fold, compared to wild-type cells in a RIG-I-dependent manner (Fig. 3e, left) . Because cKHSRP cells showed elevated RIG-I levels upon SeV infection compared to wild-type cells (Fig. 3e, middle) , it was difficult to assess whether enhanced ISG54 expression in cKHSRP is due to enhanced RIG-I signalling, or increased RIG-I protein levels. We therefore examined a system in which RIG-I levels were equalized by ectopic RIG-I expression.
We found that cKHSRP cells, even with ectopic expression of RIG-I, still showed enhancement in ISG54 induction (Fig. 3e, left) .
To further explore the structural and functional basis of KHSRP antagonism on RIG-I signalling, we examined the biochemical interaction between RIG-I and KHSRP. IFN-pretreated HEK293T cells, which have induced endogenous RIG-I protein levels, were used to immunoprecipitate RIG-I and subsequently evaluate levels of co-purifying endogenous KHSRP. Under basal conditions, we observed a stable association between RIG-I and KHSRP. However, the two proteins were found to disassociate upon SeV infection (Fig. 4a , top right) or transfection of SeV defective interfering RNA (SeV DI), a potent viral PAMP (Fig. 4a , bottom right and left) 36 . A similar interaction dynamic was observed between ectopically expressing HA-RIG-I and V5-KHSRP ( Fig. 4b, left) . We next conducted a systematic truncation analysis to further delineate the interface of interaction for both proteins. We observed that the RIG-I helicase domain (H) alone failed to pull down KHSRP, while both the RD alone and helicase plus RD (HRD) domains efficiently immunoprecipitated the KHSRP protein (Fig. 4b) . The interaction was also reconfirmed via reciprocal immunoprecipitation of V5-KHSRP and blotting for HA-RIG-I ( Supplementary  Fig. 7 ). Conversely, co-immunoprecipitation analysis of truncated KHSRP proteins revealed that interaction with RIG-I is mediated by the C-terminal domain (CTD) of KHSRP ( Fig. 4c ). Importantly, reconstitution of KHSRP knockout cells (cKHSRP) with the fulllength protein, but not the truncations lacking the CTD (that is, KH12 and KH1234), was able to reinstate KHSRP-mediated negative regulation on RIG-I signalling after challenge with either IAV or SeV infection ( Fig. 4d ). These data indicate that the physical interaction between the KHSRP CTD and RIG-I RD domains mediates repression of the signalling pathway.
KHSRP maintains a closed inactive conformation of RIG-I. In an attempt to further understand how KHSRP regulates RIG-I activity, we evaluated the impact of KHSRP depletion on specific steps of RIG-I activation. Under basal conditions, RIG-I exists in a closed conformation, coincident with phosphorylation at the Ser8 position 37 . On sensing of the vRNA PAMP after infection, RIG-I undergoes a conformational change that results in the exposure of the N-terminal CARD domain, a state that exhibits a higher sensitivity to protease digestion. In addition, dephosphorylation of the Ser8 residue, and subsequent K63-linked K172 polyubiquitination by TRIM25, results in RIG-I recruitment to MAVS and successive pathway activation 4, 10, 38 . We initially evaluated the impact of KHSRP on the conformation of RIG-I. Both wild-type and cKHSRP cell lysates expressing RIG-I were subjected to limited trypsin digestion, and sensitivity of RIG-I to protease digestion was assessed. Although comparable RIG-I levels were detected before treatment with trypsin, RIG-I was observed to possess a significantly higher sensitivity to trypsin treatment in KHSRP-deficient cells (cKHSRP). These data indicate that, in the absence of KHSRP, RIG-I adopts a conformational state that is consistent with an activated receptor state (Fig. 5a ). In agreement with this observation, RIG-I, both in the presence and absence of stimulus, harbours lower phosphorylation levels in the absence of KHSRP (Fig. 5b) . These data suggest that KHSRP binding to RIG-I results in maintenance of an inactive closed receptor conformation that promotes antagonism of the signalling pathway.
KHSRP inhibits RIG-I association with vRNA and inhibits viral replication. We next investigated whether KHSRP can modulate RIG-I sensing of vRNA PAMPs. Both wild-type and KHSRPdepleted cells, either infected with SeV ( Fig. 5c ) or transfected with SeV defective interfering (SeV DI) RNA ( Fig. 5d ), were subjected to in vivo ultraviolet crosslinking immunoprecipitation (CLIP) against endogenous RIG-I. The amount of SeV DI RNAs associated with RIG-I was assessed by quantitative reverse transcription PCR (RT-qPCR) analysis of the immunoprecipitants (see Methods) 7 . Both wild-type and KHSRP-depleted cells contained equivalent levels of RIG-I protein in the input and immunoprecipitated samples (Fig. 5c, bottom right) . The levels of SeV DI RNA were also comparable in the inputs (Fig. 5c , top right). However, in the absence of KHSRP, a significantly greater level of vRNA was found to associate with RIG-I, in comparison to wild-type cells (Fig. 5c, top left) . Conversely, reconstitution of cKHSRP knockout cells with full-length KHSRP, but not KHSRP mutants (KH12 or KH1234) or RevGFP, inhibited RIG-I association with vRNA, suggesting that KHSRP can also regulate the binding of the vRNA PAMP to RIG-I ( Fig. 5d ), possibly through competition for binding to the RIG-I RD.
Finally, we asked whether KHSRP modulation of RIG-I signalling impacted IAV replication. HEK293T cells were transfected with siRNAs against KHSRP and IAV nucleoprotein (NP), a viral protein necessary for its transcription and replication. Subsequently, the cells were infected with IAV, and viral replication levels were assessed by measuring viral titres in the supernatant. Consistent with an inhibitory Fig. 6a ). In addition, similar inhibitions on IAV and vesicular stomatitis virus (VSV) replication were observed in KHSRP-depleted NHBE and HEK293T cells, respectively ( Supplementary Fig. 8 ). The impact of KHSRP depletion on IAV replication was further investigated in vivo. Towards this end, wild-type C57BL/6 mice were administered peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) targeting KHSRP expression in the lung for two consecutive days, as we have described previously 39 .
The inhibitory effect of PPMOs on KHSRP expression was validated by western blot analysis (Fig. 6b, right) . On the following day, mice were challenged with PR8 IAV intranasally. Six days post-infection, viral titres were measured in the lungs (Fig. 6b, left) . Mice showed threefold attenuation in IAV titres upon KHSRP knockdown. Taken together, these data indicate that KHSRP-mediated regulation of innate responses impacts RNA virus replication in both cell culture and in vivo models.
Discussion
The innate immune response plays a pivotal role in the defence against infection. However, uncontrolled chronic activation of innate immune signalling can lead to cellular damage and contribute to the pathogenesis of a range of inflammatory diseases 40, 41 . Conversely, a vigorous and rapid response to microbial infection is required for pathogen clearance and initiation of humoral immunity. Thus, intricate networks of regulatory mechanisms are in place to prevent the promiscuous activation of cellular innate immune signalling pathways, but also to ensure robust activation upon pathogen encounter. In this study, using a series of unbiased global approaches, we systematically profiled the genetic and biochemical landscape of the RIG-I-dependent innate response to IAV infection. Integrative computational analysis was used to establish an extended signalling hierarchy that contained 125 positive and 187 negative regulators of the RIG-I-dependent response.
Based on network analysis of the global data sets, we identified a number of previously unappreciated biological processes and pathways that govern RIG-I-dependent innate responses, including energy metabolism (AMPK pathway; P = 1.04 × 10 −4 ), mRNA splicing (SF3A and SF3B; P = 9.95 × 10 −19 ) and canonical Wnt signaling (β-catenin activity; P = 2.87 × 10 −3 ; Supplementary  Discussion) . Interestingly, this analysis found a significant enrichment of genes that function to regulate the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress (ATXN3, STUB1 and VCP; P = 1.48 × 10 −6 ; Fig. 1d,e ). Viral infection and replication can burden normal ER functions and trigger stress responses 42 . This ER disturbance induces the unfolded protein response (UPR) to mitigate ER stress load 43 . Misfolded proteins are sensed by the ER membrane protein IRE1α to activate UPR and, interestingly, IRE1α has been reported to mediate the cleavage of cytoplasmic mRNAs to drive induction of RIG-I activation and type-I IFN responses 37, [44] [45] [46] . The co-chaperone and E3 ligase STUB1 and the de-ubiquitinating protein ATXN3 function as negative regulators of the UPR (refs [47] [48] [49] . Our study identified that both STUB1 and ATXN3 also function as negative regulators of both RIG-I signalling and IFN signalling, further supporting a critical functional coupling of RIG-I/IFN signalling and the UPR.
RIG-I sensing of non-self RNA represents a pivotal step in triggering an innate immune cascade. In this study, we found that KHSRP specifically dampens the ability of RIG-I to sense viral PAMPs. Our data indicate that KHSRP forms a stable complex with RIG-I in the absence of viral PAMP. The formation of this complex is mediated by the RD of RIG-I, which is also involved in the recognition of RNA PAMPs (Fig. 4) 50 . Our data suggest a mechanism wherein KHSRP interaction with the RIG-I RD maintains RIG-I in an inactive conformation, which may hinder PAMP association with RIG-I (Fig. 6c) . Consistent with a model in which KHSRP and PAMP RNAs compete for access to the RD of RIG-I, binding of RIG-I to SeV DI RNA increases in the absence of KHSRP (Fig. 5c,d) , while introduction of SeV DI RNA reverses the biochemical interaction of RIG-I and KHSRP (Fig. 4a,b ). We hypothesize that KHSRP antagonism of RIG-I a 12 24 36 48 h.p.i. enhances the threshold for pathway activation and augments the ability of the receptor to distinguish immunogenic and non-immunogenic RNA species. However, additional studies are required to provide a more detailed understanding of the PAMP-dependent regulation of KHSRP association with RIG-I, and the consequences of this interaction upon RIG-I binding to RNA ligands and subsequent impact on receptor activation. Taken together, this study reveals the global landscape of proteins, regulatory modules and pathways that influence RIG-Imediated innate immune signalling. Network-based analyses of these systems-level data enabled the identification of intricate crosstalk between these signalling modifiers and canonical regulators of the RIG-I signalling apparatus. These circuits likely function in concert to ensure a robust and timely response to pathogen invasion, while limiting activation by sub-threshold stimuli or attenuating prolonged responses to appropriate ligands. We anticipate that these data will be a critical resource for the community to better understand the molecular regulation that enables the precise induction of innate immune processes and promotes short-term viral control, as well as long-term protection against pathogen challenge. Importantly, deregulation of these circuits may also underlie autoimmunity and inflammatory disease. Therefore, development of therapeutics that target these regulators may facilitate the development of next-generation immune-mediated antivirals, vaccine adjuvants and therapies for autoimmune disease.
Methods
Cell culture. Wild-type HEK293T was purchased from ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 1% penicillin-streptomycin-glutamine, 1× HEPES and 1× NEAA. Authentication of these cells was performed on the GenePrint 10 System from Promega for analysis of short tandem repeats (STR) on genomic DNA. The STR profiles were analysed against databases of known STR profiles (ATCC, RIKEN, JCRB and DSMZ) and returned the best match. This was conducted by the SBP Genomics Core. HEK293T ISRE-luciferase cells were a gift from the García-Sastre laboratory and have not been authenticated 51 . Normal human bronchial/tracheal epithelial (NHBE) cells were purchased from ATCC and sourced from one donor, and were cultured in commercially available airway epithelial cell basal medium supplemented with a cell growth kit (ATCC). All tissues used for isolation of these cells were obtained under informed consent and conform to HIPAA standards to protect the privacy of the donors' personal health information, as conferred by ATCC (PCS-300-010). These primary cells were not authenticated. A recombinant human IFN-β (Avonex) or a recombinant human IFN-α/β R2 Fc chimaera (R&D Systems) was used where indicated. Doxycycline inductions of KHSRP FLAG-tagged constructs were conducted at 5 µg ml -1 for at least 24 h. Calculin A (Invitrogen, PHZ1044) treatment was conducted as described in ref. 38 . All cells were tested and were confirmed to be free of mycoplasma contamination.
RNAi, CRISPR and mutagenesis. Lipofectamine RNAiMAX (Thermo-Fisher) was used to transfect siRNAs. The following siRNAs were used: KHSRP_5 (Qiagen, SI00300587), KHSRP_3 (Qiagen, SI00054691), PIN_6 (Qiagen, SI02662667), DDX58_6 (Qiagen, SI03019646) and influenza A NP (5′-GGAUCUUAVUUCUUCGGAG-3′) 52 . The following non-targeting (nCTL) siRNAs were used as negative controls: 1776 (5′-AAGCGTTCGTGCATAGCTAAG-3′), 1777 (5′-AAGCGTTCGTCCTATGATCGA-3′) and firefly luciferase (GL3; 5′-AACTTACGCTGAGTACTTCGA-3′). The influenza A NS1 was custom designed and is available upon request from the authors. CRISPR IRF9 (cIRF9) and KHSRP (cKHSRP) HEK293T cell lines were generated according to published methods 53 . Briefly, gene-specific guide RNAs (gRNA) were designed using a publically available online design algorithm tool (http://crispr.genome-engineering.org/), and the following sgRNAs were used: ATACAGCTAAGACCATGTTC (IRF9) and CTTTCGCCGACGCCGTGCAG (KHSRP). gRNAs were cloned into pX330 plasmid (Addgene) and transfected into HEK293T cells. The pX330 (pX330-U6-Chimeric_BB-CBh-hSpCas9) was a gift from Feng Zhang (Addgene plasmid 42230) 30 . Single-cell clones of the CRISPR cells were expanded and confirmed for both protein loss and genomic mutations.
V5-tagged or FLAG-tagged, wild-type KHSRP and truncation mutants were generated by subcloning KHSRP complementary DNA (cDNA) into pLenti-V5-TOPO (Life Technologies) or pEasiLV (a gift from M. Malim), respectively 54 . The following mutants were subcloned: FL (amino acid (aa) 1-710), KH12 (aa 1-305), KH34 (aa 323-503), KH34C (aa 323-710), CTD (aa 503-710) and KH1234 (aa 1-503). Specifically, V5-tagged wild-type KHSRP and truncation mutants were generated using full-length KHSRP (FL) forward primer 5′-CACCATGTCGGACTACAGCACGGGAG-3′ and specific reverse primers that removed the STOP codon and truncated the protein from the C-terminal end: FL: 5′-ATCTCCTCTTGAACAGATG-3′; KH1234: (KH1234) 5′-CTGGTTGAAGGGCCCAGGATTG-3′; KH12: 5′-TCCGCCAATCCGAGATCCG-3′.
In addition, KHSRP domain mutants and GFP were also cloned into the doxinducible N-terminal 3× FLAG-tagged construct pEasiLV using In-Fusion HD (Clontech) cloning according to the manufacturer's protocol. The PCR forward and reverse primers for In-Fusion cloning were as follows: eGFP: 5′-GGGGCGGCCGCTCGAgtgagcaagggcgaggag-3′ and 5′-GCTGCAGATGCATCTCGATCActtgtacagctcgtccatgc-3′ FL: 5′-GGGGCGGCCGCTCGAtcggactacagcacgggag-3′ and 5′-GCTGCAGATGCATCTCGATCAatctcctcttgaacagatgaaaag-3′ KH12: 5′-GGGGCGGCCGCTCGAtcggactacagcacgggag-3′ and 5′-GCTGCAGATGCATCTCGATCAtccgccaatccgagatccgta-3′ KH34: 5′-GGGGCGGCCGCTCGAtacggatctcggattggc-3′ and 5′-GCTGCAGATGCATCTCGATCActggttgaagggcccagg-3′ KH34C: 5′-GGGGCGGCCGCTCGAtacggatctcggattggc-3′ and 5′-GCTGCAGATGCATCTCGATCAatctcctcttgaacagatgaaaag-3′ CTD: 5′-GGGGCGGCCGCTCGAcctgggcccttcaaccag-3′ and 5′-GCTGCAGATGCATCTCGATCAatctcctcttgaacagatgaaaag-3′ KH1234: 5′-GGGGCGGCCGCTCGAtcggactacagcacgggag-3′ and 5′-GCTGCAGATGCATCTCGATCActggttgaagggcccagg-3′
The N-terminal human influenza haemagglutinin (HA)-tagged RIG-I domain mutants (FL, H, RD and HRD) were a gift from the García-Sastre laboratory 36 . The reverse GFP (RevGFP) was constructed by subcloning GFP cDNA into CMV-Sport6 (Invitrogen) in the reverse orientation. This plasmid served as a negative control in the assays.
Virus and infections. Cantell SeV, H1N1 PR/8/34 (PR8) and H1N1 NS1-deleted PR8 (delNS1 PR8) IAV viruses were a gift from the García-Sastre laboratory and were amplified using 10 day embryonated chicken eggs. MHV-68 viruses were a gift from the laboratories of Ren Sun and Ting-Ting Wu (University of California, Los Angeles). The PR8 IAV infections were conducted at a multiplicity of infection (MOI) of 2 unless otherwise specified. The delNS1 PR8 IAV infections were conducted at an MOI of 0.7. IAV infections were supplemented with 3.5 µg ml -1 TPCK (Sigma) in DMEM. SeV infections were conducted at 40 haemagglutinating units (HAU) ml -1 .
Genome-wide siRNA screening. Genome-wide libraries (Qiagen, IDT, Invitrogen, GNF Druggable) comprising 98,737 synthetic siRNAs targeting 19,628 unique human genes were pre-arrayed in 384-well plates (0.5 pmol per well) such that each well contained a pool of two siRNAs in a well, with four to six total siRNAs targeting one gene in duplicates. The library matrix was introduced into HEK293T-ISREluciferase reporter cells through a reverse transfection method with lipofectamine RNAiMAX (Invitrogen) in duplicate 384-well plates. After 48 h, the cells were infected with H1N1 PR8 virus (RIG-I negative regulators) or delNS1 PR8 virus (RIG-I positive regulators) at MOIs of 1.0 and 0.7, respectively. BriteLite Plus (PerkinElmer) was added after 24 h, and the relative luminescence for each well was analysed on a Viewlux plate reader (PerkinElmer). In parallel screening plates, cytotoxicity was evaluated by measuring adenosine triphosphate levels relative to controls with CellTiterGlo (Promega).
RNAi screening analysis. To help mitigate differences of ISRE-luciferase activity between plates, all well values were first normalized to the plate median signal. Using a scaling normalization, wells were then set to the positive control siRNA (RIG-I siRNA) at an arbitrary value of 0.1, and the negative control siRNAs (non-targeting siRNAs) at 1.0 for the RIG-I positive regulator screen. Wells with lower values correspond to pathway components required for RIG-I signalling during delNS1 IAV infection (Supplementary Table 1 , scaledRAW column). For the RIG-I negative regulator screen, the positive control siRNA (IAV NS1 siRNA) was also set at an arbitrary value of 0.1 and the negative control siRNAs (non-targeting siRNAs) at 1.0 (Supplementary Table 2 , scaledRAW column). Wells with lower values corresponded to RIG-I signalling enhancement during wild-type IAV infection. Each gene was targeted by at least two sets of independent siRNA pools, and each siRNA set was run in duplicate. The reporter activities of the replicate wells were averaged to give an ISRE activity score ( Fig. 1c, Supplementary Tables 1 and 2 , Score column). The ISRE activity scores were then subjected to redundant siRNA activity (RSA) analysis, which ranks genes based on the activity of all individual siRNAs targeting a gene 21 . Genes were ranked based on log P (RSA_LogP) values, where the log P of −2 is equivalent to a P value of 0.01. Although the siRNAs were pooled to two siRNAs per well, we were able to apply RSA because each gene was targeted with a minimum of two pools and run in duplicate. See http://carrier.gnf. org/publications/RSA for the detailed RSA algorithm and procedures for analysis.
RIG-I negative regulator screen hit confirmation and triaging strategy. A total of 115 RSA-filtered hits (P < 2 × 10 −3 ) selected from the negative regulator screen based on pooled siRNAs (Supplementary Table 3 , denoted as 'RSA Hit' in the Source column, log P < −2.7) were supplemented with an additional 312 genes (Supplementary Table 3 , denoted 'Konig' in the Source column) from previously reported IAV host factors from our group 26 . We reasoned that a subset of these host factors might also function by antagonizing RIG-I-mediated innate immune signalling and thus included this in the conformation step. From a combined 427 factors, we were able to confirm the activities of 134 factors, based on the criterion of two or more independent siRNAs displaying more than 2.5-fold enhancement of ISRE-reporter activity over non-targeting controls ( Supplementary Table 3 ). We also selected 56 of these genes for additional reconfirmation assays including evaluation of endogenous ISG54 mRNA induction upon IAV infection (Supplementary Table 3 , ISG54 column). Thirty of these factors showed substantially enhanced ISG54 expression (greater than twofold; P < 0.05) upon siRNA depletion compared to the negative control. Subsequently, these 30 factors were confirmed in the cIRF9 knockout cells to identify IFN-independent regulators, and 28 factors enhanced ISG54 mRNA at least 1.5-fold ( Fig. 2a, Supplementary  Table 3 , ISG54_cIRF9 column).
Negative regulatory properties of these confirmed factors of RIG-I signalling were assessed by their ectopic expression. Twenty-five factors that enhanced ISG54 mRNA in both wild-type and cIRF9 cells upon depletion ( Fig. 2a , Supplementary Table 2 , Selected for cDNA inhibition column) were ectopically expressed in ISRE-luciferase reporter cells and subsequently infected with delNS1 IAV.
Thirteen factors reduced the reporter activity by at least 45% and were selected for RIG-I pathway mapping (Fig. 2b, Supplementary Table 2 , delNS1 column). Briefly, overexpression of either truncated RIG-I containing only the caspase activation and recruitment domains (2CARD RIG-I), MAVS or TBK1 can constitutively induce the ISRE reporter, independent of ligand ( Supplementary  Fig. 4a ). To assess inhibition at each RIG-I activation step, increasing amounts of each of these RIG-I signalling activators were co-transfected with a fixed amount of each candidate negative regulator. Statistical comparison (PRISM) between each candidate regulator and the RevGFP control (indicated as a P value) was used to determine whether the cDNA expression of the candidate blocked (blue) or did not affect (activity, yellow) ISRE-reporter activity induced by the RIG-I signalling member (P < 0.05, Fig. 2c , Supplementary Fig. 4a , Supplementary Table 3 , 2CARD_p-Val, MAVS_p-Val, TBK1_p-Val columns). Based on inhibition profiles against the four different RIG-I signalling activators (including delNS1 IAV infection), the negative regulators were grouped into four distinctive categories ( Fig. 2c and Supplementary Table 3 , Location column).
AP-MS. cDNAs of RIG-I pathway members and reported negative regulators (RIG-I, MAVS, TRIM25, NLRX1, PCBP2, PSMA7, RNF5, RNF125, DHX58, A20, IKK-ε, STING, CYLD, TBK1, IRF3, EYA4, DDX3X and PIN1) were cloned into pcDNA4/TO-3×FLAG-C (a gift from N. Krogan) and subjected to AP-MS as described in refs 39, 55 and 56. Briefly, HEK293T cells expressing each tagged protein were immunoprecipitated against FLAG tag, followed by mass-spectrometry analysis to identify co-immunoprecipitating proteins. Each affinity purification analysis was conducted in triplicate, and the data were analysed and scored with both the Mass spectrometry interaction Statistics (MiST) algorithm and CompPASS (refs 57,58) . Using MiST, reproducibility (0.32), specificity (0.68) and abundance (0.01) weights were used as previously reported 55, 57 . All bait-prey pairs with a MiST score greater than 0.70 or a top 5% CompPASS WD score were considered for further analysis.
Protein network data analyses. Protein networks were constructed for the combination of identified RIG-I negative regulators, cofactors and canonical members. Two protein-protein binding databases were compared, an aggregated public database that was previously used, and the commercial GeneGo MetaCore database (http://portal.genego.com) 26, 59 . A subset of the GeneGo interactome (v3.3.1) consisting of 814,128 interactions was extracted using the Metabase R-script library, from which we excluded low-confident interactions derived from data mining, or from publications with high-throughput screens, as well as those derived based on co-expression similarity calculations. GeneGo was later chosen for this study, because it led to a more complete network. The resultant network consists of 167 proteins and 402 interactions (P < 0.001, estimated based on 1,000 permutations; Fig. 1d and Supplementary Table 6 ). A small subnetwork was extracted based on AP-MS interactions with the RNAi hits and canonical RIG-I bait proteins (red lines). First-neighbour RNAi hits that had a direct interaction (one hop) with this subnetwork were then used to expand this network using GeneGo interaction information (blue lines, Fig. 1d ). Molecular complex detection (MCODE) analysis was applied to the 167-node RIG-I network to identify densely connected subnetworks ( Supplementary Fig. 2a ), and gene ontology analysis identified multiple enriched functional clusters ( Supplementary Fig. 2b-e ; see section 'Gene function enrichment network'). All network visualization was based on Cytoscape (http://www.cytoscape.org, version 3.3.0) 60 .
Gene function enrichment network. The 167 RIG-I network proteins were analysed with Metascape (http://metascape.org) for functional enrichment using ontology terms collected from Gene Ontology (http://geneontology.org), GeneGo pathways and processes (http://portal.genego.com), KEGG pathways and structural complexes (http://www.genome.jp/kegg), as well as multiple gene sets from MSigDB (http://www.broadinstitute.org/gsea/msigdb), including canonical pathways, hallmark gene sets, immunological signatures and chemical and genetic perturbation sets. Among them, 163 statistically significant terms were extracted through manual curation. These terms were then clustered and rendered through Metascape into an enrichment network ( Fig. 1e) , where each enriched term is depicted as a pie chart, and terms with kappa similarity >0.3 were connected to form local functional clusters. The size of a pie is proportional to the number of network proteins contained in the given ontology term. Pie sectors are sized by the portion of negative regulators versus positive regulators (red versus green, respectively). Edge width is proportional to kappa similarity and they are bundled for improved clarity. The functional network illustrator shows key biological processes that RIG-I proteins were involved in and their relationship to each other.
Digestion was stopped by the addition of SDS sample buffer and immediately boiled at 95°C for 10 min. Samples were analysed by Coomassie staining and western blotting with an anti-RIG-I (Alme-1) antibody.
Ex vivo replication. MHV-68 viral replication was measured using an MHV-68 luciferase reporter virus using BriteGlo luciferase assay (Promega) 48 h.p.i. To measure IAV and VSV viral replication, supernatant taken at the indicated time points post infection were titrated on MDCK or BHK-21 cells, respectively, and using a plaque assay as described in ref. 64 . Briefly, MDCK or BHK-21 cells were plated in 12-well plates the day before the plaque assay was performed. Tenfold serial dilutions of supernatants were adsorbed onto cells for 1 h at room temperature. The inoculum was removed, then washed with Dulbecco's PBS (dPBS) and the cells were then covered with MEM-1.25% Avicel RC581 solution (FMC Biopolymer) supplemented with TPCK-treated trypsin (2.5 µg ml -1 ) for IAV titration. After 72 h (IAV) or 36 h (VSV), cells were fixed and stained for 20 min at room temperature in one step using a solution of 0.1% crystal violet + 10% formaldehyde, and visible plaques were counted.
Animal experiments. For in vivo IAV infection studies, six-week-old C57BL/6 male mice were purchased from Jackson laboratories. Mice were anaesthetized by intraperitoneal injection of a mixture of ketamine (100 µg per g bodyweight) and xylazine (5 µg per g bodyweight) and inoculated via the intranasal route (i.n.) with the indicated 100 µg of PPMOs or PR8 influenza virus (500 plaque-forming units (p.f.u.)) in 40 µl PBS. Mice were monitored daily for weight loss and clinical signs. To measure the virus titres, lung homogenates were prepared using a FastPrep24 system (MP Biomedicals). After addition of 800 µl PBS containing 0.3% BSA, lungs were subjected to two rounds of mechanical treatment for 10 s each at 6.5 m s -1 . Tissue debris was removed by low-speed centrifugation, and virus titres in the supernatants were determined by performing tenfold serial dilutions in PBS with 0.3% BSA followed by plaque assay on MDCKII cells. For this study, mice for each experimental group (n = 5) were randomly selected and kept in separate cages throughout the experiment. The investigator was blinded to the experimental group code for measuring mouse bodyweight and viral titre in lungs. All work with animals conformed to guidelines approved by the Institutional Animal Care and Use Committee of Icahn School of Medicine at Mount Sinai.
Data availability. The data supporting the findings of this study are available within the paper and its Supplementary Information.
